Cold-adapted live influenza vaccine versus inactivated vaccine: Systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy: A meta-analysis

Vaccine

Volumn 20, Issue 9-10, 2002, Pages 1340-1353

  Beyer, W E P ^a   Palache, A M ^a   De Jong, J C ^a   Osterhaus, A D M E ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Influenza vaccines; Live influenza vaccines; Meta analysis

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; IMMUNOGLOBULIN A ANTIBODY; INACTIVATED VACCINE; INFLUENZA VACCINE;

AGE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INFECTION RISK; INFLUENZA; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STRAIN DIFFERENCE;

ADAPTATION, PHYSIOLOGICAL; ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; AGED; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; COLD; HUMANS; IMMUNOGLOBULIN A; INFANT; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRAMUSCULAR; MIDDLE AGED; VACCINES, INACTIVATED;

EID: 0037203858     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00471-6     Document Type: Article

References (89)

1. Influenza vaccines. Recommendations for the use of inactivated influenza vaccines and other preventive measures
2. Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines
3. Sequence comparison of wild-type and cold-adapted B/Ann Arbor/1/66 influenza virus genes
4. Attenuated influenza virus vaccines
5. Variability in infectivity of cold-adapted recombinant influenza virus vaccines in humans
6. Live cold-adapted, reassortant influenza vaccines (USA)
7. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults
8. Indications and contraindications for vaccines used in the expanded programme on immunization
9. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children
10. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine
11. Effect of simultaneous administration of cold-adapted and wild type influenza a viruses on experimental wild-type influenza infection in humans
12. Human influenza virus A/HongKong/156/97 (H5N1) infection
13. Advantage of live attentuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection
14. Adaptation and growth characteristics of influenza virus at 25°C
15. Options for the control of influenza
16. Is there a role for a mucosal influenza vaccine in the elderly?
17. Prevention and early treatment of influenza in healthy adults
18. Analysis of immunoglobin G antibody responses after administration of live and inactivated influenza A vaccine indicates that nasal wash immunoglobin G is a transudate from serum
19. Haemagglutination-inhibition test
20. Critical evaluation of parameters to assess the antibody response to influenza vaccination
21. Immunity to influenza A virus infection in young children: A comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine
22. Comparison of inactivated and live influenza A virus vaccines
23. Passive transfer of local immunity to influenza virus infection by IgA antibody
24. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine
25. Hemagglutinin-specific enzyme-linked immunosorbent assay for antibodies to influenza A and B viruses
26. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease
27. Some statistical methods for combing experimental results
28. Meta-analysis in clinical trials
29. Beta blockade during and after myocardial infarction: An overview of the randomized trials
30. A comparison of live and inactivated influenza A (H1N1) virus vaccines. 1. Short-term immunity
31. A comparison of live and inactivated influenza A (H1N1) virus vaccines. 2. Long-term immunity
32. Serum and nasal-wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus
33. Clinical trials with live cold-reasortment influenza virus vaccines
34. Resistance of adults to challenge with influenza A wild-type virus after receiving live or inactivated virus vaccine
35. Use of influenza A virus vaccine in seronegative children: Live cold-adapted versus inactivated whole virus
36. Comparison of long-term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine
37. Comparison of live and inactivated influenza vaccine in high risk children
38. Live attenuated and inactivated influenza vaccine in school-age children
39. Comparison of heterotypic protection against influenza A/Taiwan/86 (H1N1) by attenuated and inactivated vaccines to A/Chile/83-like viruses
40. Comparison of live, attenuated H1N1 and H3N2 cold-adapted and avian-human influenza A reassortant viruses and inactivated virus vaccine in adults
41. Serum IgG subclass antibody responses in children vaccinated with influenza virus antigens by live attenuated or inactivated vaccines
42. Family studies of vaccine efficacy in children: Comparison of protection provided by inactivated and attenuated influenza vaccines
43. Safety of and serum antibody response to cold-recombinant influenza A and inactivated trivalent influenza virus vaccines in older adults with chronic diseases
44. Local and systemic antibody responses in high-risk adults given live-attenuated and inactivated influenza A virus vaccines
45. Superiority of live attenuated compared with inactivated influenza A virus vaccines in older, chronically ill adults
46. Increased anti-influenza A virus cytotoxic T-cell activity following vaccination of the chronically ill elderly with live attenuated or inactivated influenza virus vaccine
47. Induction of mucosal antibodies by live attenuated and inactivated influenza virus vaccines in the chronically ill elderly
48. Influenza virus vaccination of patients with chronic lung disease
49. Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines
50. In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory
51. Augmentation of influenza antibody response in elderly men by thymosin alpha one. A double-blind placebo-controlled study
52. Serum IgG subclass responses of humans to inactivated and live influenza A vaccines compared to natural infections with influenza A
53. Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist(TM), administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronical medical conditions
54. Cytotoxic T lymphocyte responses of infants after natural infection or immunization with live cold-recombinant or inactivated influenza A virus vaccine
55. Human immune responses to influenza virus vaccines administered by systemic or mucosal routes
56. Live influenza vaccines
57. Studies on reactogenicity and immunogenicity of attenuated bivalent cold recombinant influenza type A (CRA) and inactivated trivalent influenza virus (TI) vaccines in infants and young children
58. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly
59. Evaluation of cold-adapted reassortant influenza B virus vaccines in elderly and chronically ill adults
60. Evaluation of live, cold-adapted influenza A and B virus vaccines in elderly and high-risk subjects
61. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses
62. A large-scale field trial of trivalent cold-adapted influenza virus live vaccine in Japan
63. Immune responses in serum and respiratory secretions following vaccination with a live cold-recombinant (CR35) and inactivated A/USSR/77 (H1N1) influenza virus vaccine
64. Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: Serological responses and clinical reactions
65. Antibody response to immunization with influenza A/USSR/77 (H1N1) virus in young individuals primed or unprimed for A/New Jersey/76 (H1N1) virus
66. Gender differences in local and systemic reactions to inactivated influenza vaccine, established by a meta-analysis of 14 independent studies
67. Effects of repeated annual influenza vaccination sero-response in young and elderly adults
68. Development and characterization of cold-adapted viruses for use as live virus vaccines
69. Comparison of live attenuated and inactivated influenza vaccines in cystic fibrosis patients and their families: Results of a 3-year study
70. Meta-analysis of randomized controlled trials. A concern for standards
71. Cold-adapted live intranasal influenza vaccine versus inactivated vaccine: Systemic reactions, antibody response, and efficacy. A meta-analysis
72. Potential hazards associated with influenza virus vaccines
73. On the origin of the human influenza virus subtypes H2N2 and H3N2
74. H5N1 influenza investigation eases fears of pandemic
75. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children
76. Influenza and the rates of hospitalization for respiratory disease among infants and young children
77. The Japanese experience with vaccinating schoolchildren against influenza
78. Immunomodulation by iscoms, immune stimulating complexes
79. The immune response of nasally administered influenza vaccine is enhanced by the polysaccharide chitosan
80. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin
81. Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers
82. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant in young adults and elderly subjects
83. Similar protection rates of influenza live and inactivated vaccines in all age groups. A meta-analysis